Parveen K Garg1, Weihua Guan2, Amy B Karger3, Brian T Steffen3, Matthew Budoff4, Michael Y Tsai3. 1. Division of Cardiology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. Electronic address: parveeng@med.usc.edu. 2. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA. 3. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA. 4. Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, USA.
Abstract
BACKGROUND: Lipoprotein (a) [Lp(a)] is a risk factor for coronary heart disease and calcific aortic valve disease. We determined the relationships of Lp(a) with prevalence and progression of coronary artery calcification (CAC), mitral annular calcification (MAC), and thoracic aortic calcification (TAC) in a multi-ethnic cohort of middle to older-aged adults. METHODS: This analysis included 6705 Multi-Ethnic Study of Atherosclerosis participants. Lp(a) was measured with a turbidimetric immunoassay. CAC, MAC, and TAC were assessed by cardiac computed tomography both at baseline and once during follow-up. RESULTS: In adjusted relative risk regression cross-sectional analysis, a Lp(a) level ≥50 mg/dL was associated with a 22% higher prevalence of MAC (relative risk (RR) = 1.22, 95% confidence interval (CI) 1.00, 1.49). No significant associations were observed for prevalent CAC or TAC. In adjusted prospective analyses, participants with Lp(a) ≥50 mg/dL were at significantly higher risk for rapid CAC progression (median follow-up = 8.9 years), defined as ≥100 units/year, compared to those with lower Lp(a) levels (RR = 1.67, 95% CI = 1.23, 2.27). The association between higher Lp(a) levels and incident CHD was no longer significant after adjusting for CAC progression. No significant associations were observed for MAC or TAC progression (median follow-up = 2.6 years). CONCLUSIONS: Higher Lp(a) levels are associated with more rapid CAC progression. Additional study is needed to better understand how this relationship can further improve the ability of Lp(a) to enhance cardiovascular disease risk prediction.
BACKGROUND: Lipoprotein (a) [Lp(a)] is a risk factor for coronary heart disease and calcific aortic valve disease. We determined the relationships of Lp(a) with prevalence and progression of coronary artery calcification (CAC), mitral annular calcification (MAC), and thoracic aortic calcification (TAC) in a multi-ethnic cohort of middle to older-aged adults. METHODS: This analysis included 6705 Multi-Ethnic Study of Atherosclerosis participants. Lp(a) was measured with a turbidimetric immunoassay. CAC, MAC, and TAC were assessed by cardiac computed tomography both at baseline and once during follow-up. RESULTS: In adjusted relative risk regression cross-sectional analysis, a Lp(a) level ≥50 mg/dL was associated with a 22% higher prevalence of MAC (relative risk (RR) = 1.22, 95% confidence interval (CI) 1.00, 1.49). No significant associations were observed for prevalent CAC or TAC. In adjusted prospective analyses, participants with Lp(a) ≥50 mg/dL were at significantly higher risk for rapid CAC progression (median follow-up = 8.9 years), defined as ≥100 units/year, compared to those with lower Lp(a) levels (RR = 1.67, 95% CI = 1.23, 2.27). The association between higher Lp(a) levels and incident CHD was no longer significant after adjusting for CAC progression. No significant associations were observed for MAC or TAC progression (median follow-up = 2.6 years). CONCLUSIONS: Higher Lp(a) levels are associated with more rapid CAC progression. Additional study is needed to better understand how this relationship can further improve the ability of Lp(a) to enhance cardiovascular disease risk prediction.
Authors: Michael G Silverman; Michael J Blaha; Harlan M Krumholz; Matthew J Budoff; Ron Blankstein; Christopher T Sibley; Arthur Agatston; Roger S Blumenthal; Khurram Nasir Journal: Eur Heart J Date: 2013-12-23 Impact factor: 29.983
Authors: Imad Nadra; Justin C Mason; Pandelis Philippidis; Oliver Florey; Cheryl D W Smythe; Geraldine M McCarthy; Robert C Landis; Dorian O Haskard Journal: Circ Res Date: 2005-05-19 Impact factor: 17.367
Authors: Matthew J Budoff; Khurram Nasir; Ronit Katz; Junichiro Takasu; J Jeffery Carr; Nathan D Wong; Matthew Allison; Joao A C Lima; Robert Detrano; Roger S Blumenthal; Richard Kronmal Journal: Atherosclerosis Date: 2010-11-26 Impact factor: 5.162
Authors: Iftikhar J Kullo; Kent R Bailey; Lawrence F Bielak; Patrick F Sheedy; George G Klee; Sharon L Kardia; Patricia A Peyser; Eric Boerwinkle; Stephen T Turner Journal: Mayo Clin Proc Date: 2004-10 Impact factor: 7.616
Authors: G Dangas; R Mehran; P C Harpel; S K Sharma; S M Marcovina; G Dube; J A Ambrose; J T Fallon Journal: J Am Coll Cardiol Date: 1998-12 Impact factor: 24.094
Authors: Matthew J Budoff; Rebekah Young; Victor A Lopez; Richard A Kronmal; Khurram Nasir; Roger S Blumenthal; Robert C Detrano; Diane E Bild; Alan D Guerci; Kiang Liu; Steven Shea; Moyses Szklo; Wendy Post; Joao Lima; Alain Bertoni; Nathan D Wong Journal: J Am Coll Cardiol Date: 2013-03-26 Impact factor: 24.094
Authors: Caroline S Fox; Helen Parise; Ramachandran S Vasan; Daniel Levy; Christopher J O'Donnell; Ralph B D'Agostino; Jonathan F Plehn; Emelia J Benjamin Journal: Atherosclerosis Date: 2004-04 Impact factor: 5.162
Authors: Olufunmilayo H Obisesan; Minghao Kou; Frances M Wang; Ellen Boakye; Yasuyuki Honda; S M Iftekhar Uddin; Omar Dzaye; Albert D Osei; Olusola A Orimoloye; Candace M Howard-Claudio; Josef Coresh; Roger S Blumenthal; Ron C Hoogeveen; Matthew J Budoff; Kunihiro Matsushita; Christie M Ballantyne; Michael J Blaha Journal: J Am Heart Assoc Date: 2022-06-03 Impact factor: 6.106
Authors: Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet Journal: Metabolism Date: 2021-01-07 Impact factor: 8.694